Daniel O'Day
Daniel O'Day is the CEO of Gilead Sciences, a biopharmaceutical company known for its innovative treatments for various diseases, including HIV. Under his leadership, Gilead has made significant advancements in the development of antiviral therapies, including the recent approval of Yeztugo, a promising new injectable treatment for the prevention of HIV. O'Day has been a key figure in the biotech industry, advocating for accessible healthcare solutions and emphasizing the importance of addressing global health challenges.
Not in the pool (under ¢1).
Recent news mentions
Daniel O'Day, Gilead Sciences' chairman and CEO, said efforts were underway to authorize distribution of the drug.
US delivers HIV prevention drug to two African states
Kenya· 2025-11-18
Gilead Chairman and CEO Daniel O’Day announced that the company is providing lenacapavir at no profit to reach up to two million people.
WHO recommends twice-a-year HIV prevention shot
Ghana· 2025-07-14
Gilead Chairman and CEO Daniel O’Day announced that the company is providing lenacapavir at no profit to reach up to two million people.
WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight
United States· 2025-07-14Gilead CEO Daniel O’Day expressed hope that U.S. aid spending to fight the epidemic will resume.
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries
Guyana· 2025-07-10Gilead chairman and chief executive Daniel O'Day said in a statement.
US approves Gilead's twice-yearly injection to prevent HIVKenya· 2025-07-01Daniel O'Day is the chairman and CEO of Gilead Sciences, who stated that the approval of the injection is a historic day in the fight against HIV.
Americký úrad schválil injekciu na prevenciu HIV
Slovakia· 2025-06-20
Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
Autoridades de saúde dos EUA aprovam primeira vacina contra VIH-Sida | VIH
Portugal· 2025-06-20
Daniel O'Day, president and CEO of Gilead, described the approval as a 'key moment in the decades-long fight against HIV'.
¿Cómo es el nuevo tratamiento preventivo contra el VIH aprobado por EE.UU. y por qué podría marcar un antes y un después con su eficacia cercana al 100% |Yeztugo | Estados Unidos | Sida | TECNOLOGIA
Peru· 2025-06-19
Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
EUA aprovam primeiro tratamento preventivo contra HIV/SIDA
Mozambique· 2025-06-19Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
Autoridades de saúde dos Estados Unidos aprovam primeira vacina contra VIH-SIDA
Cabo Verde· 2025-06-19Daniel O'Day is the president and CEO of Gilead who declared the approval of a new treatment for HIV prevention as a historic day.
Estados Unidos aprobó un nuevo tratamiento para prevenir el VIH | Sida | Yeztugo | Gilead | EE.UU. | TECNOLOGIAPeru· 2025-06-19Daniel O'Day, the CEO of the American biotechnology company Gilead, announced the approval of the drug as a historic day in the fight against HIV.
أمل جديد.. أميركا تجيز علاجاً واعداً لفيروس نقص المناعة البشرية
United Arab Emirates· 2025-06-19
Daniel O'Day, president and CEO of Gilead, described the approval as a 'key moment in the decades-long fight against HIV'.
Primera inyección preventiva para el VIH es aprobada en EE.UU. - Mundo
Paraguay· 2025-06-19Daniel O'Day is the president and CEO of Gilead who declared the approval of a new HIV prevention treatment as a historic day.
Aprueban tratamiento preventivo contra el VIH
Dominican Republic· 2025-06-19
Daniel O'Day, president and CEO of Gilead, described the approval as a 'key moment in the decades-long fight against HIV'.
Estados Unidos aprueba la primera inyección preventiva para el VIH aplicada cada seis meses
Panama· 2025-06-19Daniel O'Day is the president and CEO of Gilead, the company developing the new HIV prevention treatment.
Estados Unidos aprueba nuevo tratamiento preventivo contra el VIH; "es un día histórico", afirma laboratorio
Mexico· 2025-06-18
Daniel O'Day, the head of the American biotech company Gilead, praised the approval of the new treatment as a historic day in the fight against HIV.
Les Etats-Unis approuvent un traitement préventif très prometteur contre le VIH, évoquant « un jour historique » dans la lutte contre le sida
France· 2025-06-18